Geoffrey Garin on PhRMA National Survey
When asked about the link between vaccines and autism, an alarming 25% of Americans and 30% of parents believe that vaccines can cause autism in young children, according to our Second Annual National Health Survey for PhRMA. This is striking in that it comes despite reputable authorities like the CDC and the Mayo Clinic clearly stating that there is no link between vaccines and autism.
Additionally, gluten-free diets are all the rage these days and nearly two in three (65%) Americans believe that many people are sensitive to gluten, even if they don’t have Celiac disease. Recent research, however, contradicts this cla...
Source: PHRMA - September 24, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Geoffrey Garin
PresidentGeoffrey Garin has been the president of Hart Research Associates since 1984. In this capacity, Mr. Garin has undertaken landmark policy and communications research for many of the nation’s leading foundations, educational institutions and progressive organizations. Democrats at the national and state levels have relied on Mr. Garin to direct their polling and develop winning strategies for their campaigns. Mr. Garin is a graduate of Harvard College.
HartSurveyspages/Peter-Hart-Research-Associates/159464630740611Conversations ContributorsCompany: Hart Research Associates (Source: PHRMA)
Source: PHRMA - September 24, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Which of the findings of the PhRMA National Health Survey was most surprising to you, and why?
Geoffrey Garin on PhRMA National Survey
Submitted by Emily on Tue, 09/23/2014 - 20:50
When asked about the link between vaccines and autism, an alarming 25% of Americans and 30% of parents believe that vaccines can cause autism in young children, according to our Second Annual National Health Survey for PhRMA. This is striking in that it comes despite reputable authorities like the CDC and the Mayo Clinic clearly stating that there is no link between vaccines and autism.
Share
Email
Print
var switchTo5x = false;var __st_l...
Source: PHRMA - September 22, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Margaret Foti, PhD, MD (hc)
CEOMargaret Foti, PhD, MD (hc), is chief executive officer of the American Association for Cancer Research. The AACR is the oldest and most prestigious cancer research organization in the world. Under her visionary leadership, it has grown to more than 34,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates in more than 90 countries, and is renowned as the world’s leading organization dedicated to the prevention and cure of cancer. A graduate of Temple University, Foti has been one of the most influential voices in advancing the field of can...
Source: PHRMA - September 18, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
John P. Howe, III, M.D.
President and CEOJohn P. Howe, III, M.D., became President and CEO of Project HOPE in 2001.
Before coming to Project HOPE, Dr. Howe was the Distinguished Chair in Health Policy at The University of Texas Health Science Center at San Antonio and served as the Center’s chief executive for fifteen years. Dr. Howe is board certified in both internal medicine and cardiovascular disease.
Dr. Howe has a bachelor’s degree from Amherst College and earned his medical degree from Boston University School of Medicine. He served two years in the Army Medical Corps and later completed the Health Systems Management Program at Harva...
Source: PHRMA - September 11, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Raymond Schinzi Video
(Source: PHRMA)
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Julie Source Type: news
Phill Wilson: What are you excited about in the fight against HIV/AIDS?
Where There’s A Will
We are at a deciding moment in the trajectory of the AIDS epidemic in the United States. As a result of recent scientific advances, we have something that just a few years ago, we couldn’t even imagine—the promise of an AIDS free generation. We actually have the tools to end the AIDS epidemic, at least in the U.S. We have better diagnostic tools, better surveillance tools, better treatment tools, and better prevention tools.
But we have to be careful. Sometimes we confuse being able to do something with actually doing it. The question is less can we end the AIDS epidemic and more do we ...
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Travis Sherer: What are you excited about in the fight against HIV/AIDS?
Founded in 1982 in direct response to the AIDS epidemic, GLMA has long been involved in issues related to HIV and AIDS. Although progress has been challenging at times, there is a lot right now to be hopeful about. Significant advances in the treatment and prevention of HIV have led us to an exciting place where we are able to discuss the potential for an end to the epidemic. Condom use, antiretroviral therapies, microbicides, PreP (pre-exposure prophylaxis) and PEP (post-exposure prophylaxis) provide a wide range of tools available help prevent the transmission of HIV. Treatment as prevention is real and within our gra...
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Travis Sherer
PA-C, AAHIVSTravis Sherer, PA-C, AAHIVS, has been a board member for GLMA: Health Professionals Advancing LGBT Equality since 2008. He is the Program Manager of the Lenox Hill Retroviral Disease Center in New York City. Travis is also a past president of the LBGT PA Caucus of the American Academy of Physician Assistants.
A longtime volunteer at GMHC and other non-profit organizations, Travis is a passionate believer in service to marginalized populations. In 2004, he founded the Health Equity Project, a non-profit organization dedicated to improving health and access to health care in developing countries. Travis was a c...
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Phill Wilson
President and CEOPrior to founding the Institute, Wilson served as the AIDS Coordinator for the City of Los Angeles from 1990 to 1993, the Director of Policy and Planning at AIDS Project Los Angeles from 1993 to 1996. He was co-chair of the Los Angeles County HIV Health Commission from 1990 to 1995, and was an appointee to the HRSA AIDS Advisory Committee from 1995 to 1998.
Wilson was the coordinator of the International Community Treatment and Science Workshop at the 12th, 13th, 14th, 15th, and 16th International AIDS Conferences in Geneva, Switzerland; Durban, South Africa; Barcelona, Spain; Bangkok, Thailand; an...
Source: PHRMA - September 10, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Jim Sullivan on Improving the Lives of Patients
At AbbVie, research and innovation are the cornerstones of our business as a global biopharmaceutical company. We focus on developing medicines that deliver strong clinical performance, provide more patient benefit and deliver economic value, particularly where there is significant need around the world in certain disease areas.
Arthritis is an example of a disease where we have the opportunity to continue to make headway to improve the lives of patients. According to the U.S. Centers for Disease Control and Prevention (CDC) prevalence of musculoskeletal diseases could increase from 52 million people in the U.S. to 67 mi...
Source: PHRMA - September 9, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
What are you excited about in the fight against HIV/AIDS?
Lawrence Stallworth: What are you excited about in the fight against HIV/AIDS?
Submitted by Emily on Tue, 09/09/2014 - 12:16
When I was 17 years old, I found out I was HIV-positive. As a young, Black gay man, I remember the fear of rejection, and the incredible love and support I found among my family and friends. Since the day I first learned my HIV status, I have made it my personal responsibility to fight this disease until we achieve an AIDS-free generation. I know many young people out there feel the same because our risk of infection is high and access to treatment and care c...
Source: PHRMA - September 9, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Kathie Hiers: What are you excited about in the fight against HIV/AIDS?
We have made amazing advances in the field of HIV in the last 33 years. Everyone knows how much better the medications are. Antiretroviral therapy (ART) today has fewer side effects, reduced pill burdens, and better efficacy. And then our world was turned upside down by the incredible discovery of HIV Prevention Trials Network 052! We now know that persons living with HIV who are successful on and adherent to ART and who reach an undetectable viral load essentially cannot transmit the disease to others. As a result, providers are scrambling to make sure that folks know their status, that all positive persons have...
Source: PHRMA - September 9, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Kathie Hiers
CEOKathie Hiers has been active in the fight against HIV/AIDS since the epidemic first hit the South in the mid-1980′s. Kathie has served as the CEO of AIDS Alabama since January 2002. Prior to that, she was the Executive Director of Mobile AIDS Support Services and a founder of the Lee Simmons Fund for People Living with AIDS in Mobile, Alabama.
Kathie is one of 25 people appointed to the Presidential Advisory Council on HIV/AIDS, providing advice and expertise to the President and the Secretary of Health and Human Services. She is also a member of the Planning Committee for the White House Summit on HIV and the Sout...
Source: PHRMA - September 9, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
Bill Arnold: What are you excited about in the fight against HIV/AIDS?
In this week’s Conversations Blog, I’m outlining some of the points that I find most salient in our continuing fight against HIV/AIDS in the United States. First and foremost, it is imperative that we continue to strive for an effective “cure” (Sustained Virologic Response – SVR – in this case to Antiretroviral Therapies) beyond that which we currently consider to be the standard (“Undetectable” Viral Load). While suppressing the Viral Load in HIV patients is essential to ensuring that they maintain good health, it is also a vital tool in helping to prevent the spread of HIV between serodiscordant sexual pa...
Source: PHRMA - September 9, 2014 Category: Pharmaceuticals Authors: Emily Source Type: news
